Laquinimod

Jump to: navigation, search
Template:Chembox E number
Laquinimod
Laquinimod.png
Names
IUPAC names
5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-
N-phenyl-1,2-dihydroquinoline-3-carboxamide
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
UNII
Properties
C19H17ClN2O3
Molar mass 356.803 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is ☑Y☒N ?)
Infobox references

WikiDoc Resources for Laquinimod

Articles

Most recent articles on Laquinimod

Most cited articles on Laquinimod

Review articles on Laquinimod

Articles on Laquinimod in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Laquinimod

Images of Laquinimod

Photos of Laquinimod

Podcasts & MP3s on Laquinimod

Videos on Laquinimod

Evidence Based Medicine

Cochrane Collaboration on Laquinimod

Bandolier on Laquinimod

TRIP on Laquinimod

Clinical Trials

Ongoing Trials on Laquinimod at Clinical Trials.gov

Trial results on Laquinimod

Clinical Trials on Laquinimod at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Laquinimod

NICE Guidance on Laquinimod

NHS PRODIGY Guidance

FDA on Laquinimod

CDC on Laquinimod

Books

Books on Laquinimod

News

Laquinimod in the news

Be alerted to news on Laquinimod

News trends on Laquinimod

Commentary

Blogs on Laquinimod

Definitions

Definitions of Laquinimod

Patient Resources / Community

Patient resources on Laquinimod

Discussion groups on Laquinimod

Patient Handouts on Laquinimod

Directions to Hospitals Treating Laquinimod

Risk calculators and risk factors for Laquinimod

Healthcare Provider Resources

Symptoms of Laquinimod

Causes & Risk Factors for Laquinimod

Diagnostic studies for Laquinimod

Treatment of Laquinimod

Continuing Medical Education (CME)

CME Programs on Laquinimod

International

Laquinimod en Espanol

Laquinimod en Francais

Business

Laquinimod in the Marketplace

Patents on Laquinimod

Experimental / Informatics

List of terms related to Laquinimod

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS).

Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide.[1]

The compound has been investigated in two Phase II trials using successive magnetic resonance scans (MRI). Laquinimod seems to be able to reduce the MS disease activity on MRI.[2][3] However, the response to a given dose was discrepant between both studies.[4]

Phase III studies for MS started in December 2007.[5] In 2011, Teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce relapses into MS among patients beyond a placebo.[6] However, the final results of above-mentioned phase III trial proved oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing–remitting multiple sclerosis.[7]

See also

  • Fingolimod, a marketed drug with the same mechanism of action
  • Ponesimod, an experimental drug with the same mechanism

References

  1. Tan IL; Lycklama à Nijeholt GJ; Polman CH; et al. (April 2000). "Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials". Mult Scler. 6 (2): 99–104. doi:10.1191/135245800678827626. PMID 10773855. Unknown parameter |author-separator= ignored (help)
  2. Comi G; Pulizzi A; Rovaris M; et al. (June 2008). "Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study". Lancet. 371 (9630): 2085–2092. doi:10.1016/S0140-6736(08)60918-6. PMID 18572078. Unknown parameter |author-separator= ignored (help)
  3. Polman C; Barkhof F; Sandberg-Wollheim M; et al. (March 2005). "Treatment with laquinimod reduces development of active MRI lesions in relapsing MS". Neurology. 64 (6): 987–91. doi:10.1212/01.WNL.0000154520.48391.69. PMID 15781813. Unknown parameter |author-separator= ignored (help)
  4. Keegan BM, Weinshenker BG (June 2008). "Laquinimod, a new oral drug for multiple sclerosis". Lancet. 371 (9630): 2059–2060. doi:10.1016/S0140-6736(08)60894-6. PMID 18572062.
  5. Clinical trial number NCT00509145 for "Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)" at ClinicalTrials.gov
  6. Kresege, Naomi (1 August 2011). "Teva's Copaxone Successor Fails in Latest Clinical Trial". Bloomberg. Retrieved 2 August 2011. Teva Pharmaceutical Industries Ltd. (TEVA)’s experimental multiple sclerosis pill failed to reduce relapses more than placebo in a clinical trial, dealing a blow to the company’s effort to find a successor to an older drug.
  7. Template:Cite doi

External links

Multiple sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Alternative Therapies

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Laquinimod On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Laquinimod

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Laquinimod

CDC on Laquinimod

Laquinimod in the news

Blogs on Laquinimod

Directions to Hospitals Treating Multiple sclerosis

Risk calculators and risk factors for Laquinimod


Linked-in.jpg